UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies

Alzheimer's research & therapy, 2016-02, Vol.8 (8), p.8-8, Article 8

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Respiratory research, 2024-02, Vol.25 (1), p.107-107

2024

Link zum Volltext

Verfügbarkeit prüfen

A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients

The journal of clinical endocrinology and metabolism, 2004-02, Vol.89 (2), p.638-645

2004

Link zum Volltext

Verfügbarkeit prüfen

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Blood, 2008-04, Vol.111 (8), p.4022-4028

2008

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Respiratory research, 2024-02, Vol.25 (1)

2024

Link zum Volltext

Verfügbarkeit prüfen

Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE®-RL)

Expert opinion on drug delivery, 2018-06, Vol.15 (6), p.545-548

2018

Link zum Volltext

Verfügbarkeit prüfen

A Longitudinal Item Response Theory Model to Characterize Cognition Over Time in Elderly Subjects

CPT: pharmacometrics and systems pharmacology, 2017-09, Vol.6 (9), p.635-641

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Cancer, 2009-02, Vol.115 (3), p.551-560

2009

Link zum Volltext

Verfügbarkeit prüfen

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

Blood, 2006-09, Vol.108 (5), p.1478-1484

2006

Link zum Volltext

Verfügbarkeit prüfen

ITEM RESPONSE THEORY (CERAD, CVLT)

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P433-P433

2014

Link zum Volltext

Verfügbarkeit prüfen

P4‐185: UP‐TITRATION TO HIGH‐DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_23), p.P856-P857

2014

Link zum Volltext

Verfügbarkeit prüfen

P1‐329: ITEM RESPONSE THEORY (CERAD, CVLT)

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_11), p.P433-P433

2014

Link zum Volltext

Verfügbarkeit prüfen

UP-TITRATION TO HIGH-DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY

Alzheimer's & dementia, 2014-07, Vol.10 (4), p.P856-P857

2014

Link zum Volltext

Verfügbarkeit prüfen

Incidence and predictors of response to the 13.3 (15 cm2 ) and 9.5 mg/24h (10 cm2 ) rivastigmine patch in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study

Alzheimer's & dementia, 2013-07, Vol.9 (4), p.P656-P657

2013

Link zum Volltext

Verfügbarkeit prüfen

P3–275: Incidence and predictors of response to the 13.3 (15 cm2) and 9.5 mg/24h (10 cm2) rivastigmine patch in the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study

Alzheimer's & dementia, 2013-07, Vol.9 (4S_Part_16), p.P656-P657

2013

Link zum Volltext

Verfügbarkeit prüfen

P3–278: The rivastigmine high‐dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study

Alzheimer's & dementia, 2013-07, Vol.9 (4S_Part_16), p.P658-P658

2013

Link zum Volltext

Verfügbarkeit prüfen

The rivastigmine high-dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study

Alzheimer's & dementia, 2013-07, Vol.9 (4), p.P658-P658

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease

American journal of Alzheimer's disease and other dementias, 2013-09, Vol.28 (6), p.583

2013

Link zum Volltext

Verfügbarkeit prüfen

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

Alzheimer's research & therapy, 2015-03, Vol.7 (1), p.9-9, Article 9

2015

Link zum Volltext

Verfügbarkeit prüfen

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Cancer, 2010-08, Vol.116 (15), p.3750-3750

2010

Link zum Volltext

Verfügbarkeit prüfen

The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients

Clinical endocrinology (Oxford), 2005-08, Vol.63 (2), p.176-184

2005

Link zum Volltext

Verfügbarkeit prüfen

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Blood, 2009-11, Vol.114 (22), p.337-337

2009

Link zum Volltext

Verfügbarkeit prüfen

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization

Blood, 2008-11, Vol.112 (11), p.2124-2124

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(30)
Buchkapitel
(1)

Sprache

Englisch
(31)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Humans
(10)
Treatment Outcome
(9)
Aged
(8)
Biological And Medical Sciences
(7)
Female
(7)
Male
(7)
Medical Sciences
(7)
Middle Aged
(7)
Adult
(5)
Benzamides
(5)
Hematologic And Hematopoietic Diseases
(5)
Imatinib Mesylate
(5)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(5)
Neurology
(5)
Double-Blind Method
(4)
Leukemia, Myeloid, Chronic-Phase - Drug Therapy
(4)
Adolescent
(3)
Aged, 80 And Over
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE®-RL)

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

A Longitudinal Item Response Theory Model to Characterize Cognition Over Time in Elderly Subjects

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

ITEM RESPONSE THEORY (CERAD, CVLT)

P4‐185: UP‐TITRATION TO HIGH‐DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY

P1‐329: ITEM RESPONSE THEORY (CERAD, CVLT)

UP-TITRATION TO HIGH-DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH AND MEMANTINE: RESULTS FROM THE OPTIMA STUDY

Incidence and predictors of response to the 13.3 (15 cm2 ) and 9.5 mg/24h (10 cm2 ) rivastigmine patch in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study

P3–275: Incidence and predictors of response to the 13.3 (15 cm2) and 9.5 mg/24h (10 cm2) rivastigmine patch in the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study

P3–278: The rivastigmine high‐dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study

The rivastigmine high-dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study

Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization

Suchergebnisse filtern